RxDoctor Payments Data

Susan Evans

Family · Warner Robins, GANPI 1376143446

Payments from drug & device makers

$10,430in general payments, 2019–2025

Across 586 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$857
  • Lilly USA, LLC$779
  • Novo Nordisk$652
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$611
  • Otsuka America Pharmaceutical, Inc.$587
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$10,430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,430 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$1,683
Medicare patients
12
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$83,018
JardianceEmpagliflozin26$38,729
LinzessLinaclotide31$37,539
MounjaroTirzepatide21$35,785
EliquisApixaban29$34,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,851
FarxigaDapagliflozin Propanediol16$20,876
JanuviaSitagliptin Phosphate16$18,392
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$18,360
MyrbetriqMirabegron13$16,529
TrulicityDulaglutide13$12,728
GemtesaVibegron20$12,510
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$10,531
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$9,042
Aimovig AutoinjectorErenumab-Aooe12$8,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$652$83,01864 claims
Lilly USA, LLCMounjaro, Trulicity$779$48,51334 claims
AbbVieLinzess, Synthroid$1,198$40,34461 claims
AstraZenecaFarxiga, Breztri Aerosphere$528$39,23631 claims
Boehringer IngelheimJardiance$205$38,72926 claims
GSKTrelegy Ellipta, Anoro Ellipta$402$35,89341 claims
PfizerEliquis$484$34,73929 claims
MerckJanuvia$96$18,39216 claims
Astellas Pharma US IncMyrbetriq$186$16,52913 claims
Sumitomo Pharma America, Inc.Gemtesa$79$12,51020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →